The phase III LITESPARK-012 compares pembrolizumab plus lenvatinib, with or without belzutifan or quavonlimab (an anti-CTLA4-Ab) as first-line treatment in advanced ccRCC [15]. The gene discussed is CTLA4; the disease is nonpapillary renal cell carcinoma.